Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for HARVONI
- Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19)
- Effect of Hepatitis C Clearance on Insulin Resistance
- Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19
- A Study of Sofosbuvir and Ledipasvir From Soviredia 90/400 mg Tablets (Minapharm, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)
- Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus
- Hepatitis C Positive Donor Into Hepatitis C Negative Recipients
- Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection
- Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma
- The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs
- Harvoni Treatment Porphyria Cutanea Tarda
- A Study of Sofosbuvir and Ledipasvir From Magicbuvir Plus 90/400 mg Tablets (Magic Pharma, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)
- Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World
- DAA in the Risk of Recurrence After Curative Treatment of HCC
- Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea
- Hepatitis C Virus(HCV) Heart and Lung Study
- Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection
- Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
- Study of Oral Treatments for Hepatitis C
- Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C)
- Extrahepatic Insulin Resistance in Chronic Hepatitis C
- Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics
- Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
- Study of Hepatitis C Treatment During Pregnancy
- HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection
- Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes
- Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy
- LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients
- 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
- Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection
- Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection
- Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant
- Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)
- Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection
- Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6
- Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs
- Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia
Clinical trials list
click for details